- Home
- SCSC vs ZYME Comparison
SCSC vs ZYME Comparison
Compare SCSC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCSC
- ZYME
- Stock Information
- Founded
- SCSC 1992
- ZYME 2003
- Country
- SCSC United States
- ZYME United States
- Employees
- SCSC N/A
- ZYME N/A
- Industry
- SCSC Retail: Computer Software & Peripheral Equipment
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- SCSC Technology
- ZYME Health Care
- Exchange
- SCSC Nasdaq
- ZYME Nasdaq
- Market Cap
- SCSC 732.8M
- ZYME 761.2M
- IPO Year
- SCSC 1994
- ZYME 2017
- Fundamental
- Price
- SCSC $31.74
- ZYME $11.53
- Analyst Decision
- SCSC Hold
- ZYME Buy
- Analyst Count
- SCSC 1
- ZYME 6
- Target Price
- SCSC N/A
- ZYME $19.50
- AVG Volume (30 Days)
- SCSC 359.4K
- ZYME 833.8K
- Earning Date
- SCSC 05-06-2025
- ZYME 05-08-2025
- Dividend Yield
- SCSC N/A
- ZYME N/A
- EPS Growth
- SCSC N/A
- ZYME N/A
- EPS
- SCSC 2.54
- ZYME N/A
- Revenue
- SCSC $3,021,788,000.00
- ZYME $76,304,000.00
- Revenue This Year
- SCSC N/A
- ZYME $26.29
- Revenue Next Year
- SCSC $6.35
- ZYME $75.78
- P/E Ratio
- SCSC $12.52
- ZYME N/A
- Revenue Growth
- SCSC N/A
- ZYME 0.38
- 52 Week Low
- SCSC $28.75
- ZYME $7.97
- 52 Week High
- SCSC $53.90
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- SCSC 40.08
- ZYME 49.31
- Support Level
- SCSC $30.75
- ZYME $10.69
- Resistance Level
- SCSC $31.75
- ZYME $11.48
- Average True Range (ATR)
- SCSC 1.57
- ZYME 0.78
- MACD
- SCSC 0.12
- ZYME 0.10
- Stochastic Oscillator
- SCSC 50.68
- ZYME 81.57
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.